Skip to main content

Table 5 Frequencies of treatment-emergent adverse events (TEAEs)* (safety population)

From: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

Category of TEAE

Pegfilgrastim 6 mg (N = 101)

Lipegfilgrastim 6 mg (N = 101)

n (%)

n (%)

Any TEAE

99 (98.0)

100 (99.0)

Drug-related TEAE = TEADR

26 (25.7)

28 (27.7)

Serious TEAE

7 (6.9)

3 (3.0)

Serious TEADR

1 (1.0)

1 (1.0)

Severe TEAE

35 (34.7)

26 (25.7)

Severe TEADR

2 (2.0)

1 (1.0)

Discontinued due to TEAE

2 (2.0)

3 (3.0)

Discontinued due to TEADR

1 (1.0)

0 (0)

Death

0 (0)

1 (1.0)

  1. *Patients could be counted in multiple categories.
  2. TEAE treatment-emergent adverse event; TEADR treatment-emergent adverse drug reaction.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us